Kovač, Mirjana (7102654168)Mirjana (7102654168)KovačBasarić, Dušica (57898708800)Dušica (57898708800)BasarićTomić, Branko (14421786200)Branko (14421786200)TomićGvozdenov, Maja (55937902600)Maja (55937902600)GvozdenovBacković, Dragana (55856937600)Dragana (55856937600)BackovićLalić-Ćosić, Sanja (56464253200)Sanja (56464253200)Lalić-Ćosić2025-06-122025-06-122022https://doi.org/10.2298/VSP210217101Khttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85148037968&doi=10.2298%2fVSP210217101K&partnerID=40&md5=4d7341b819781b3f846d77babcfa4803https://remedy.med.bg.ac.rs/handle/123456789/3672Background/Aim. Direct oral anticoagulants (DOACs) administration significantly interferes with coagulation as-says. The aim of the study was to evaluate the effect of DOACs and DOAC-Remove® on coagulation assays dur-ing thrombophilia testing. Methods. The study was car-ried out from January 2019 to the end of June 2020. It in-cluded 30 DOAC-treated patients, 14 females and 16 males aged 23 to 63 (median age 47.6 years), tested for thrombophilia due to venous thromboembolism (VTE). Thrombophilia testing was performed using DOAC-Remove® tablets (activated charcoal). The results before and after DOAC-Remove® were compared. Results. Posi-tive lupus anticoagulant (LA) results were observed in 20% apixaban, 100% dabigatran, and 70% rivaroxaban-treated patients, while in samples after DOAC-Remove®, the LA positivity was observed only in one from the apix-aban group. Before DOAC-Remove®, the activated pro-tein C (APC) resistance (APC-R) was measurable in 40% dabigatran and 80% rivaroxaban-treated patients, while, after using DOAC-Remove®, the APC-R was measurable in all cases. Comparing the results obtained from the sam-ples before and after DOAC-Remove®, a difference was noted in relation to all dilute Russell's viper venom time (dRVVT) coagulation tests, except for the dRVVT ratio in the apixaban group. Clot-based methods for detecting the APC resistance were significantly affected by dabigatran and less by rivaroxaban. Conclusion. DOACs were prac-tically inactivated after the addition of the DOAC-Remove®, which made it possible to perform analyses for the LA and APC-R testing freely and obtain relevant re-sults. © 2022 Inst. Sci. inf., Univ. Defence in Belgrade. All rights reserved.anticoagulantsblood coagulation testsevaluation studythrombophilia